Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

PROFIT ALERT — REDUCTION IN LOSS

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the Board's preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the "**Reporting Period**"), and the information currently available to the Board, the Group expects to achieve revenue growth and a reduction in loss. The key financial highlights are as follows:

KEY FINANCIAL HIGHLIGHTS (FOR THE REPORTING PERIOD)

(i) Revenue Growth: Revenue for the six months ended June 30, 2026 is expected to be approximately RMB125.7 million to RMB130.8 million, representing a year-on-year increase of approximately 24.0% to 29.0% compared to RMB101.3 million for the six months ended June 30, 2025.

(ii) Reduction in Loss: Loss attributable to equity shareholders for the six months ended June 30, 2026 is expected to be approximately RMB69.0 million to RMB73.5 million, representing a year-on-year reduction of approximately 39.5% to 43.2%; negative earnings before interest, taxes, depreciation, and amortization ("**EBITDA**") for the six months ended June 30, 2026 is expected to be approximately RMB44.4 million to RMB49.0 million, representing a year-on-year reduction of approximately 46.9% to 51.9%.

I. PRINCIPAL REASONS FOR REVENUE GROWTH

During the Reporting Period, the Group's revenue growth was primarily driven by the following factors:

(i) The Group further expanded its presence in the pre-implantation genetic testing ("**PGT**") market, establishing core products with strong profitability. Driven by regulatory tailwinds and increasing market penetration, the Group recorded robust revenue growth. During the Reporting Period, the PGT-M Kit received Class III medical device registration certificate from the National Medical Products Administration of China ("**NMPA**") in April 2026, becoming the first domestically developed PGT-M product in China specifically targeting familial thalassemia genetic prevention, filling a gap in the domestic market for home-grown pre-implantation genetic testing for monogenic disorders, and providing a compliant domestically-produced technological tool for the implementation of national monogenic disease prevention and treatment policies. The first PGT-A Kit based on a fully domestic sequencing platform received the NMPA Class III medical device registration certificate in March 2026. The Group has achieved a fully domestically-produced closed-loop from sequencers to reagents, further consolidating its first-mover advantage as a leading domestically-certified enterprise.

On the demand side, clinical demand for embryo genetic screening has continued to rise amid the trend of delayed childbearing. Combined with the nation's continued efforts to strengthen birth defect prevention and treatment, pre-implantation genetic testing, as a critical technological tool for preventing monogenic disease transmission from the source and achieving primary prevention of birth defects, has clinical value that is highly consistent with policy direction, with the industry entering an important policy window.

(ii) Gems culture medium received the NMPA's approval for market launch, becoming another important product pipeline with stable revenue contribution for the Group. Following two years of registration filing, the Group's Gems series culture medium achieved intensive full-range commercialization during the Reporting Period. Following the approval of the one-step embryo culture medium by the NMPA in February 2026, fertilization culture medium, blastocyst culture medium and cleavage embryo culture medium were subsequently approved. The Group became the first domestic brand in the Chinese assisted reproduction market to offer a full range of culture media supported by large-scale clinical trial data.

The Gems culture media technology originated from the Sydney IVF Centre and was led by Professor David Mortimer, known as the "Father of Culture Media". The products have previously obtained three major international authoritative certifications, including the US Food and Drug Administration ("**FDA**"), the European conformity (conformité européenne) ("**CE**"), and the Therapeutic Goods Administration of Australia ("**TGA**") certifications, and have been widely used in over 600 reproductive centers across more than 20 countries worldwide. The Group has successfully achieved domestic market launch of high-quality international products and further implemented domestic production conversion. In addition, leveraging solid clinical evidence, the Gems culture media enabled the Group to establish the "Geri Time-lapse Incubator + Gems Culture Media + AI Embryo Assessment System" undisturbed embryo culture product matrix, further enhancing customer stickiness and diversifying revenue sources.

(iii) The Group's overseas market revenue maintained steady growth during the Reporting Period, with the Asia-Pacific region recording growth of approximately 50%, a particularly strong performance, and South Korea, Japan, Thailand and Vietnam emerging as key growth drivers. With the continued increase in equipment installation volume, coupled with the growth in ancillary consumable sales, the Group achieved simultaneous volume growth in both equipment and consumables.

Meanwhile, the Group's overseas product pipeline continued to broaden. PGT kits and gene sequencers have been installed in nearly 10 reproductive centers across Europe and Asia-Pacific, bringing the Group sustained repeat purchase revenue and expected growth. The independently developed ultra-low temperature storage device Gelida 800 completed its first overseas delivery during the Reporting Period. By expanding its overseas product pipeline, the Group has opened up new growth opportunities for its overseas business.

II. PRINCIPAL REASONS FOR REDUCTION IN LOSS

During the Reporting Period, the Group's loss attributable to equity shareholders narrowed year-on-year, which was primarily attributable to:

(i) Registration and filing for the Group's core products have been substantially completed, with research and development investment correspondingly declining, and the Group has fully shifted its focus to commercialization. The Group has become one of the few platform-type companies globally in the assisted reproduction industry covering genetic testing, embryo culture, andrology testing, cryopreservation and software/AI ecosystem, establishing a comprehensive product portfolio and regulatory compliance barriers. The combination of equipment hardware with consumable and service revenue demonstrates strong sustainability and expected growth potential.

(ii) With the continued advancement and pipeline expansion of overseas business, the Group's overseas segment continued to achieve improvement in revenue and profitability, becoming an important growth driver for the Group.

(iii) As the Group's revenue scale continued to expand and gross profit margin improved, coupled with the continued implementation of refined management practices, the input-output efficiency of selling, administrative and research and development expenses continued to improve, with operating performance trending positively.

The Company is still in the process of finalizing the results of the Group for the six months ended June 30, 2026. The information contained in this announcement is based solely on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026, which have not been reviewed by the audit committee of the Board nor audited or reviewed by the independent auditors of the Company. The information contained in this announcement may be different from the actual interim results of the Group for the six months ended June 30, 2026, and may be subject to adjustment.

For detailed information regarding the Group's 2026 interim results, Shareholders and potential investors are advised to refer to the interim results announcement of the Group for the six months ended June 30, 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, the PRC, August 16, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.